Stock IMMNOV IMMUNOVIA AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Immunovia AB

Equities

IMMNOV

SE0006091997

Market Closed - Nasdaq Stockholm
Other stock markets
 11:59:58 08/05/2024 BST 		5-day change 1st Jan Change
1.734 SEK -3.88% Intraday chart for Immunovia AB -14.58% -2.14%
04-29 Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024
04-29 Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina
CI
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test
CI
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test
MT
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study
CI
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development
CI
Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
CI
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test
CI
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Sweden's Immunovia Forms R&D Partnership With Switzerland's Proteomedix
MT
Immunovia Launches Strategic Partnership with Proteomedix to Leverage R&D Efforts with Increased Focus on Commercialization
CI
Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d
CI
Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMNOV Stock
  4. News Immunovia AB
  5. Highlights